Elizabeth Spencer

Assistant Professor

Mount Sinai Hospital

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Elizabeth Spencer is an Assistant Professor at Mount Sinai Hospital Mount Sinai Heart in the United States. Her research areas include inflammatory bowel disease, with recent publications focusing on the effectiveness of various treatments such as Adalimumab, Upadacitinib, and Risankizumab. Dr. Spencer also explores the implications of glucocorticoid-induced adrenal insufficiency and the role of genetics in very early-onset inflammatory bowel disease.

Articles (12)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Michael Dolinger

Assistant Professor of Pediatric Gastroenterology, Associate Pediatric Gastroenterology Fellowship Program Director

UNITED STATES

View details

Daniel Kotlarz

Heisenberg Professorship, Precision medicine in pediatric inflammatory bowel disease

Dr von Haunersches Kinderspital Kinderklinik und Kinderpoliklinik der Ludwig Maximilian Universität München

GERMANY

View details

Parakkal Deepak

Washington University in Saint Louis School of Medicine

UNITED STATES

View details

Christopher Ma

Assistant Professor

University of Calgary

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Elizabeth Spencer

Research Interests

Explore related searches

Contact this professor

About

Articles (12)

Evaluation and Management of Glucocorticoid-Induced Adrenal Insufficiency in IBD: An Expert Opinion

Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study

Effectiveness and Safety of Adalimumab in Patients With Very Early-Onset Inflammatory Bowel Disease: A Retrospective Study on Behalf of the Porto Inflammatory Bowel Disease Working Group of European Society for Pediatric Gastroenterology Hepatology and Nutrition

Risankizumab Is Effective for The Management of Crohn’s Disease of the Pouch

Determining the Accuracy of Intestinal Ultrasound Scores as a Prescreening Tool in Crohn's Disease Clinical Trials

Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease

A Single-Center Experience with Dupilumab for Atopic or Psoriasiform Dermatitis in Patients with Inflammatory Bowel Disease

Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients

Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.

Very Early Onset Inflammatory Bowel Disease: A Clinical Approach With a Focus on the Role of Genetics and Underlying Immune Deficiencies.

Real-World Experience With Acute Infusion Reactions to Ustekinumab at 2 Large Tertiary Care Centers

Inflammatory Bowel Disease Clusters Within Affected Sibships in Ashkenazi Jewish Multiplex Families.

Collaborators (4)

Michael Dolinger

Daniel Kotlarz

Parakkal Deepak

Christopher Ma

Make your next move.